Expedience of conventional radiotherapy in locally advanced cervix cancer: A retrospective analysis
|
|
- Sybil Lewis
- 5 years ago
- Views:
Transcription
1 Original Article Expedience of conventional radiotherapy in locally advanced cervix cancer: A retrospective analysis Prakash Bhagat, Sanjoy Roy, Debarshi Lahiri, Tapas Maji, D. K. Ray, Jaydip Biswas, P. Chaudhuri Department of Radiation Oncology, Chittaranjan National Cancer Institute, Kolkata, West Bengal, India Address for the Correspondence: Dr. Sanjoy Roy, C/56, Survey Park, Kolkata , West Bengal, India. E mail: sanjoyroy56@gmail.com Access this article online Website: DOI: / Quick response code: Abstract Objective: Analysis was done to assess the implications of total radiation treatment duration towards locally advanced cervical cancer. Methods: A comparative study was conducted in CNCI, Kolkata. A total of 38 patients were studied with interdigited brachyttherapy during the course of conventional teleradiotherapy and they were compared to a total of 39 patients with conventional sequential teletherapy and brachytherapy. Results: In the experimental arm all the patients had complete response to treatment whereas, 24 patients (85.7%) in the conventional arm had complete response [P = 0.08]. At the last follow up 28 patients (73.68%) in the study arm and 17 patients (43.58%) in the control arm were free of disease. The failure rate in the conventional control arm was significantly higher [P = 0.035]. Test of proportion derived from data also showed that the proportion of patients with no evidence of disease at the time of last follow-up was significantly higher in the study arm compared to the control arm [P < 0.05] and the proportion of patients with persistent disease was significantly less in the stuwdy arm compared to the control arm [P < 0.05]. The probability of disease-free survival in percentage according to the curve at the time of median follow-up was approximately 70% for study arm and 60% for control arm [log-rank test, P = ]. Conclusion: we should hence minimize treatment time and avoid any planned or unplanned interruptions or delays by timely integration of external beam and intra-cavitary irradiation that may yield a better local control in locally advanced cervical cancer. Key words: Brachytherapy, cervix cancer, radiotherapy, treatment duration INTRODUCTION An estimated 371,000 new cases of invasive cervical cancer are diagnosed worldwide each year, representing 10% of all cancers in women. In developing countries, cervical cancer has been the most frequent neoplastic disease among women especially in a rural area until date. [1,2] Worldwide; cervical cancer is the fifth most frequent cause of cancer deaths in women, causing about 9 deaths per 100,000/year. In Southeast Asia, cancer cervix has been a big challenge since long due to poor socioeconomic reason. Age adjusted incidence rates of cervical cancer range from 19 to 44 per 100,000 women in various cancer registries in India. It has been estimated that about 120,000 women in India newly develop cervical cancer and approximately 80,000 die of the disease every year. [3] Nearly 80% of cervical cancers are diagnosed in our country at stage III or above when there is very little scope of definitive therapy. Locally advanced cervical cancer, that is, stages IIB; III and IVA are treated with radiotherapy alone or with a combination of chemotherapy and radiotherapy. Radiotherapy duration could be the most independent treatment related prognostic factor in cervical cancer. It has been suggested that the mechanism for patients with longer treatment durations exhibiting a greater risk of local relapse could be the accelerated repopulation of tumor clonogens surviving a course of radiotherapy. Though concomitant chemo radiotherapy is currently recommended as the standard treatment protocol for advanced stages of cervical cancer on the basis of results of some randomized trials as per 85 Oncology, Gastroenterology and Hepatology Reports Jul-Dec 2015 Vol 4 Issue 2
2 National Cancer Institute (NCI) alert, [4 8] in our institution, like many other institutions in India locally advanced cervical cancer patients had been treated with radiotherapy alone instead of concomitant chemo radiotherapy in early part of first decades of this century. This is due to the following reasons: Nearly 90% of our advanced cervical cancer patients present in stage IIIB. The benefit of concomitant chemo radiotherapy in stage IIIB cancer of the cervix is not yet convincingly proved [9] Poor in nutritional status to tolerate chemo radiotherapy for the full course Non affordability to the cost of chemotherapy and supportive therapy such as granulocyte colony stimulating factor, etc. Chemotherapy purposefully was not included in this study due to its potential to aggravate the toxicities of concomitant telebrachytherapy and affect the outcome. It is recommended that radiation therapy for cervical cancer patients should be delivered in the shortest possible overall time. [10] External beam radiotherapy (EBRT) if inter phased with intracavitary radiotherapy (ICRT), the total duration of treatment can be drastically reduced. The total duration of treatment in the conventional radiation protocol of EBRT followed by ICRT is around 9 weeks. If ICRT is given concomitantly with EBRT, the duration can be brought down to approximately 5 weeks. From radiobiological point of view, the second approach is likely to be more effective, and there is ample evidence that this approach is radiobiologically acceptable. The rational for using concomitant EBRT and ICRT is to shorten the overall duration of treatment by radiotherapy. If the surviving tumor clonogen doubled every 3 days during the latter 3 weeks of treatment, as they do, for example in irradiated squamous cell carcinomas of head and neck [11 13] the effective number of cells to be eradicated would increase by a factor 27. This roughly 100 fold increase in cell number is equivalent, for example, to about a 2 or even 3 unit increase in T stage. Lanciano et al. had analyzed an increase in actuarial 4 year infield recurrence from 5% to 20% occurred when total treatment time increased from <6 weeks to 10+ weeks (P = ) as well as significantly decreased survival too (P = ). [14] Ferrigno et al. [15] performed a retrospective analysis of 138 patients to report results of patients with cancer cervix treated by EBRT and interdigitated high dose rate ICRT. Overall 5 year survival and local control rates were 81.5% and 84% versus 44.6% and 53% for patients with treatment duration up to 50 days and those with treatment duration >50 days, respectively. Objectives The two therapeutic modalities were compared in terms of the following parameters as response to treatment, acute toxicities, disease free survival, and long term complications. MATERIALS AND METHODS The retrospective case control study was performed at Chittaranjan NCI, Kolkata from September 2005 to May Patients with histologically confirmed cervical cancer belonging to stage IIB to IVA having minimum Karnofsky Performance Score of 70 were assigned to Study arm and Control arm (natural selection). The study compared concomitant EBRT and ICRT (Study Arm) with sequential EBRT, followed by ICRT (Control Arm). Treatment protocol for study arm (concomitant external beam radiotherapy and intracavitary radiation therapy) Patients received external beam radiation to the whole pelvis up to a total dose of 50 Gy, delivered in 25 fractions over 5 weeks. Teletherapy was delivered to the pelvis by AnteroPosterior PosteroAnterior (AP PA) fields by Tele cobalt ( 60 Co). The borders for the AP PA fields were superiorly the junction of the L 4 L 5 vertebra, inferiorly 1 cm below the lower border of obturator foramen and laterally 1 cm lateral to the pelvic wall. If the inter field distance (IFD) was >18 cm, two lateral fields were added in spite of two AP PA fields only. The superior and inferior borders for the lateral fields were the same as for the AP PA fields. The anterior border was at the level of the symphysis pubis and the posterior border at the junction of the S 2 S 3 vertebral body. High dose rate brachytherapy was delivered with Ir 192 point source by remote after loading system under short anesthesia. Applicators used were intra uterine tandems (IUT) and rings of various sizes and angles selected according to the patient s geometry. Bladder was marked by putting a Foley s catheter and inflating the balloon with 7 ml of radio opaque dye. Rectum was marked by putting into it a radio opaque flexible marker. Simulation was done using Mecaserto Axsim II simulator to individualize each patient s treatment. Doses to bladder point, rectal point, and Point A were defined according to ICRU 38 recommendations. 60 Simulation and planning was carried out on the day of each ICRT application. During the first 2 weeks of therapy, EBRT was administered only and was given from Monday to Friday. From 3 rd week onwards, ICRT was administered and was given on Thursday and EBRT was given from Monday to Wednesday and on Friday and Saturday. Second and third fractions of ICRT were given during the 4 th and 5 th week of treatment with EBRT. Dose of radiation given by ICRT was 7 Gy per fraction weekly for 3 such fractions. Treatment protocol for control arm (sequential external beam radiotherapy followed by intracavitary radiotherapy) Patients received external beam radiation to the whole pelvis up to a total dose of 50 Gy, delivered in 25 fractions over 5 weeks. The machines, field sizes and other details were same as followed in the study arm. In this arm, intracavitary brachytherapy was started 2 weeks after the completion of teletherapy. The dose and Oncology, Gastroenterology and Hepatology Reports Jul-Dec 2015 Vol 4 Issue 2 86
3 procedure of brachytherapy was same as described in the study arm. Here, the average duration for completion of therapy came to about 9 weeks. During radiotherapy, patients were assessed weekly, and complications were graded according to the Radiation Therapy Oncology Group Cancer Therapy Evaluation Program 8 Revised March 23, 1998 Common Toxicity Criteria, Version 2.0 DCTD, NCI, NIH, DHHS. [16] Follow up After the completion of therapy, patients were evaluated 2 weeks and 6 weeks after the completion of therapy and 3 monthly thereafter. Patients response was classified as per RACIST criteria. If any growth was found in the cervix on follow up, its size and extent were noted with obtainment of a punch biopsy and time calculation was noted. Total duration of treatment included both the external beam and intracavitary components of therapy and was calculated in calendar days starting from the day of first fraction of EBRT. RESULTS Intracavitary radiotherapy inter phased with EBRT was delivered to 38 patients (Study Group) and ICRT following EBRT was delivered to 39 patients (Control Group). The mean age of the patients was 50.1 ± 9.8 years. The median age at marriage of the cervical cancer patients was 16 year, and the median age at first childbirth was 19 year. The mean parity was 3.9 ± 1.9. In the study group, 55.3% were postmenopausal and in the control group the proportion was 66.7% (P = 0.22). Majority of the patients in the study were in stage IIIB (74.0%), and the rest were in stage IIB (26.0%) (P = 0.41). The most common histopathological diagnosis was squamous cell carcinoma in either of the groups (P = 0.60). The morphological characteristics of the tumors did not have any significant difference (P = 0.59). Pretreatment evaluation of the patients The pretreatment performance status was similar (P = 0.60). The pretreatment mean hemoglobin levels of the patients in the study group and in the control group were 11.1 ± 1.2 g/dl and 11.2 ± 1.0 g/dl, respectively, (P = 0.69). On ultra sonography, 11.7% of the total patients had significantly enlarged pelvic lymph nodes. The percentage of patients having enlarged pelvic nodes was similar in the study group (10.5%) and the control group (12.8%). Radiation therapy details Majority of the patients in either treatment group completed the EBRT within 6 weeks. Treatment was completed as per protocol in 34 patients of the study group and 31 patients in the control group. In the study group, 3 patients had incomplete EBRT and no ICRT at all. In the same group, 1 patient had incomplete EBRT and only a single insertion of ICRT. In the control group, 6 patients received incomplete EBRT and no ICRT. In the same group, 1 patient completed EBRT, but received no ICRT and 1 patient received 2 insertions of ICRT after complete EBRT (P = 0.50). The most commonly used IFD was cm in either treatment group (P = 0.19). Mean dose of radiation given by EBRT till the time of first ICRT insertion to patients in the study arm was Gy (range Gy), and the mean dose of radiation given by EBRT till the time of 2 nd and 3 rd ICRT were Gy (range Gy) and Gy (range Gy), respectively. ICRT was given to all patients in the control arm after the completion of EBRT, and thus they had received a full dose of 50 Gy with EBRT before ICRT was given. Overall 3 patients in the study group and 7 patients in the control group did not receive any ICRT. Majority of the patients in either of the groups had ICRT using an IUT of size 60 mm. Rest of the patients were treated using the IUT of size 40 mm. The details of size of IUT used are shown in Table 1 (P = 0.68). The vaginal Table 1: Uterine tandem size used IUT size Study Control Total 40 mm mm Total IUT: Intra uterine tandem Table 2: Vaginal ring used Ring size Study Control Total 26 mm mm Total Table 3: Radiation dose to the urinary bladder Bladder dose (percentage Study Control Total of dose to point A) < and above Total Table 4: Radiation dose to the rectum Rectal dose (percentage Study Control Total of dose to point A) < Total Oncology, Gastroenterology and Hepatology Reports Jul-Dec 2015 Vol 4 Issue 2
4 ring size used depended on the pliability of the vagina and the space available for insertion. The most commonly used size was 30 mm, followed by 26 mm. The details of the ring size used are given in Table 2 (P = 0.40). The calculated radiation dose to the bladder mucosa was <80% of the dose to point A in 76.4% of patients (77.8% in study group and 75% in control group) shown in Table 3 (P = 0.37). The calculated radiation dose to the rectal mucosa was < 80% of dose to point A in 98.2% patients (100.0% in study group and 96.4% in the control group) shown in (P = 0.38) Table 4. The duration of therapy was calculated in days starting from the day of first fraction of EBRT till the last dose of radiation (EBRT or ICRT as applicable) and was converted to weeks. Due to concomitant use of EBRT and ICRT nearly all patients in the study group could complete therapy within 7 weeks (33/34; 97%). In the control Table 5: Duration of treatment arm wise Duration of therapy Study Control Total 4 weeks weeks weeks weeks weeks weeks weeks weeks weeks Total patients in study group and 8 patients in the control group did not complete treatment Table 6: Treatment interruption arm wise Duration of interruption Study Control Total 1-5 days days days days days Total group due to application of ICRT after completion of EBRT the proportion of patients completing radiation therapy within 7 weeks was significantly less (2/33; 6.1%) (P = 0.00) [Table 5]. Treatment was interrupted in 9 patients of the study group and 10 patients of the control group. In the majority of the patients, the interruption did not exceed 10 days (P = 0.36) [Table 6]. The level of difficulty of insertion was noted during each ICRT application and was graded according to a scale of 1 5 (1 = very easy, no difficulty at all; 5 = extremely difficult, procedure abandoned). During the first insertion level 3 or worse difficulty was encountered in 31 patients in the study group (88.6%) and 26 patients in the control group (81.3%) (P = 0.61). During second insertion same level of difficulty (level 3 or worse) was encountered in 11 patients (32.4%) and 4 patients (12.5%) in the study group and the control group, respectively, (P = 0.05). The number of patients in whom level 3 or worse difficulty was observed came down to 3 (8.8%) in study group and 0 in control group during the 3 rd insertion of ICRT (P = 0.09) [Table 7]. The recruited patients were periodically examined and investigated for the occurrence of any acute toxicity. Intestinal obstruction developed in two patients (1 in each arm of the study) after 5 days and 8 days of starting radiation, respectively. The intestinal obstruction was attributed to the disease process rather than to the treatment and was not considered as toxicity. Both these patients died within a week of diagnosis of intestinal obstruction. The most commonly encountered toxicity was drop in hemoglobin (P = 0.80). Compared to anemia the other hematological toxicity, leucopenia was observed much less frequently (P = 0.51). Grade 1 or 2 anorexia was observed in a significant number of patients treated by either modality (P = 0.41). Radiation induced dermatitis (grade 2 3) was observed more frequently in the study group (P = 0.58). The other frequently encountered dermatological toxicity was the pruritus that was mild in most of the cases and was similar in both the arms (P = 0.09). Dysuria and urinary frequency and urgency were the common bladder related toxicities encountered (For Table 7: Levels of difficulty encountered during different ICRT applications Study group Control group Level 1 Level 2 Level 3 Level 4 Level 5 Total Level 1 Level 2 Level 3 Level 4 Level 5 Total 1 st ICRT nd ICRT rd ICRT ICRT: Intra cavitary radiotherapy Table 8: Arm wise comparison of complications Symptom Study (n=33) Control (n=28) Grade 1 (%) Grade 2 (%) Grade 3 Total (%) Grade 1 (%) Grade 2 (%) Grade 3 Total (%) Proctitis 2 (6) 1 (3) 0 3 (9) 3 (11) 1 (4) 0 4 (14) Diarrhoea 3 (9) 2 (6) 0 5 (15) 4 (14) 3 (11) 0 7 (25) Bladder 3 (9) 1 (3) 0 4 (12) 2 (7) 1 (4) 0 3 (11) Vaginal stenosis 2 (6) 1 (3) 0 3 (9) 4 (14) 2 (7) 0 6 (21) Genital edema 4 (12) 1 (3) 0 5 (15) 2 (7) 1 (4) 0 3 (11) Oncology, Gastroenterology and Hepatology Reports Jul-Dec 2015 Vol 4 Issue 2 88
5 dysuria P = For frequency/urgency: P =0.12). Among the gastro intestinal toxicities, diarrhea and proctitis were observed in both the groups (For diarrhea: P = For Proctitis: P =0.92) [Table 8]. Follow up after therapy The patients were followed up at 2 weeks, 6 weeks and subsequently every 3 months after completion of radiation therapy. The median duration of follow up for the patients completing therapy (n = 65) was 312 days from the initiation of treatment (minimum 75 days; maximum 541 days). Of the total 77 patients recruited in the study, 65 completed treatments. Of them, 61 patients came for at least one follow up visit and in these patients response to treatment could be evaluated. Treatment could not be completed only in 2 patients (1 in each arm) due to intestinal obstruction developing within 10 days of initiation of treatment. It is likely that the complication was due to advanced disease process rather than due to therapy. In the study arm, all the patients had a complete response to treatment. In contrast to that, 24 patients (85.7%) in the control arm had complete response (P = 0.08). The late complications (complications observed after 180 days of starting of treatment) are listed in Table 8. In the study group, there were total 20 instances of late complications where in the control group was 23. At the last follow up, 28 patients in the study arm and 17 patients in the control arm were free of disease. There were 2 pelvic recurrences and 2 metastatic diseases in the study arm. The corresponding values in the control arm were 6 and 0, respectively. One patient in study arm and 1 patient in control arm had combined pelvic and distant failures. The failure rate in the control arm was significantly higher (P = 0.035). Test of proportion derived from the above data also showed that the proportion of patients with no evidence of disease at the time of last follow up was significantly higher in the study arm compared to the control arm (P < 0.05). The proportion of patients having persistent disease was significantly less in the Figure 1: Test statistics for equality of survival distributions study arm compared to the control arm (P < 0.05). There was no significant difference for pelvic recurrence, metastatic disease and pelvic recurrence with metastatic disease (P > 0.05). The disease free survivals in the study and control arm are shown by Kaplan Meier analysis in Figure 1. The probability of disease free survival in percentage according to the curve at the time of median follow up was approximately 70% for study arm and 60% for control arm (log rank test, P = ). DISCUSSION Radiation therapy is the treatment of choice for patients with stage IIB, and III carcinoma of the uterine cervix (dose to point A is Gy delivered by combining brachytherapy and EBRT). It is believed that in the treatment of cancer, an improvement in loco regional control should lead to improved disease free survival. [17,18] In radiotherapy, increment of the local dose can improve the local control but at the cost of increased frequency of complications. [19] Loco regional control of primary cancer also depends on the duration in which the entire course of radiotherapy is given. It was very well demonstrated by Denekamp [20] that proliferation of the epithelium of the skin or mucosa accelerates 2 or 3 weeks after initiation of radiation. Withers et al. [13] experimentally documented the acceleration of repopulation of tumor cells after fractionated radiation therapy and Fowler [21] emphasized the importance of rapid proliferation of malignant cells as a factor influencing tumor control probability. Baumann et al. [22] reported in a series of experiments in nude mice bearing a human squamous cell carcinoma, a progressive increase in TCD 50 with longer periods of treatment time ranging from 2 to 10 weeks, with radiation doses ranging from 43 to 102 Gy: The loss of tumor control dose was 1 Gy/day with prolongation of time. Oka et al. [23] observed that radiation doses of 5.4 Gy to 9 Gy increase the number of cycling squamous tumor cells in G 1 or G 2 phase and that transient increase was attributable to the combined effects of recruitment of the cycling cells and G 1 or G 2 block. Keane et al. [24] was the first to report decreased pelvic tumor control in carcinoma of the cervix for stages I and II as 0.7%/day and for stages III and IV as <1.2%/day due to the above effect. Fyles et al. [25] demonstrated the adverse effect of increased treatment duration on pelvic tumor as loss of tumor control of 1%/day of treatment prolongation beyond 30 days, and it was predominantly observed predominantly in stages III and IV. Suguwara et al. [26] also noted a significant increase in pelvic recurrences in 97 patients with stage III IV disease receiving doses of 93 Gy or greater to Point A when overall treatment time was longer than 42 days (40 41%) compared with patients treated in shorter times (10 18%). Girinsky et al. [27] in a study of 386 patients with stage IIB to III carcinoma of the cervix treated with irradiation also observed a loss of tumor control and overall survival when the treatment time exceeded 52 days. A 1.1% loss of pelvic tumor control per day was observed. 89 Oncology, Gastroenterology and Hepatology Reports Jul-Dec 2015 Vol 4 Issue 2
6 According to Kapp et al. [28] stage of the disease as a pretreatment factor was found to be significantly correlated with incidence and severity of late sequelae. In the early stage IB disease, a favorable anatomy permits optimal placement of applicators with maximum sparing of normal tissues. In advanced stages eccentric growth or shrinkage of initially large tumors often result in uni or bilateral flattening of the vaginal fornices or cause vaginal narrowing, which impede optimum placement of applicators thus causing over exposure of normal tissues and more complications. Thus, the point of significance is the volume of normal tissue irradiated to high doses with brachytherapy rather than the maximum doses calculated at specified points. While considering EBRT, the factors that came into play were varying external beam doses, treatment position, choice of energy, 2 versus 4 field technique, number of fields treated per day, fractionation and daily dose, customized blocking, use of mid line shield or side wall boost influenced the nature and likelihood of complications. For brachytherapy, the different factors had been the choice of isotope, applicator design, combination of IUT with ring applicators, cylinders, shielded or nonshielded ovoids, loading technique, treatment plans standardized or individualized according to the patient, dose specifications, isodose distribution and maximum doses to adjacent normal tissues. The practical conclusion is that in the treatment of patients of carcinoma of the uterine cervix with radiation therapy, we should minimize treatment time and avoid any planned or unplanned interruptions or delays by timely integration of external beam and intracavitary irradiation. REFERENCES 1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990: Int J Cancer 1999;80: Ferlay J, Parkin DM, Pisani P. GLOBOCAN 1. Cancer Incidence and Mortality Worldwide. IARC. Cancer Base No. 3. Lyon: IARC Press; Chaudhury K. Indian Trends in Cervical Cancers. Recent Developments of Cancer of Uterine Cervix. 6 th Annual Symposium. New Delhi: Ranbaxy Scientific Foundation; p Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, SuggsS CL 3 rd, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999;340: Peter WA 3 rd, Liu PY, Barrett RJ 2 nd, Stock RJ, Monk BJ, Berek JS, et al. Cisplatin, 5-fluorouracil plus radiation therapy are superior to radiation therapy as adjunctive therapy in high risk, early stage carcinoma of the cervix, after radical hysterectomy and pelvic lymphadenectomy; Report of a phase III intergroup study. J Clin Oncol 2000;18: Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannijan EV, Fowler WC Jr, et al. Randomized comparison of 5 Fluorouracil plus Cisplatin versus Hydroxyurea as an adjunct to radiation therapy in stage IIA IVA carcinoma of cervix with negative para aortic lymph nodes; A Gynecologic Oncologic Group and South West Oncology Group study. J Clin Oncol 1999;17: Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;340: Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para aortic radiation for high risk cervical cancer. N Engl J Med 1999;340: Basu P, Biswas J, Mandal R, Choudhury P. Is interferon alpha and retinoic acid combination along with radiation superior to chemo radiation in the treatment of advanced carcinoma of cervix? Indian J Cancer 2006;43: Perez CA, Grigsby PW, Castro Vita H, Lockett MA. Carcinoma of the uterine cervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy. Int J Radiat Oncol Biol Phys 1995;32: Maciejewski B, Withers HR, Taylor JM, Hliniak A. Dose fractionation and regeneration in radiotherapy for cancer of the oral cavity and oro pharynx: Part I, Tumor dose response and repopulation. Int J Radiat Oncol Biol Phys 1989;16: Withers HR, Peters LJ, Taylor JM, Owen JB, Morrison WH, Schultheiss TE, et al. Local control of carcinoma of the tonsil by radiation therapy: An analysis of patterns of fractionation in nine institutions. Int J Radiat Oncol Biol Phys 1995;33: Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988;27: Lanciano RM, Pajak TF, Martz K, Hanks GE. The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: A patterns of care study. Int J Radiat Oncol Biol Phys 1993;25: Ferrigno R, Santos Novaes PE, Pellizzon AC, Dos Santos Novaes PE, Conte Maia MA, Ferrigno R, Fogarolli R, Salvajoli JV, et al. High dose rate brachytherapy in the treatment of uterine cervix cancer: Analysis of dose effectiveness and late complications. Int J Radiat Oncol Biol Phys 2001;50: Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, et al. Common toxicity criteria: Version 2.0. An improved reference for grading the acute effects of cancer treatment: Impact on radiotherapy. Int J Radiat Oncol Biol Phys 2000;47: DeVita VT, Lippman M, Hubbard SM, Ihde DC, Rosenberg SA. The effect of combined modality therapy on local control and survival. Int J Radiat Oncol Biol Phys 1986;12: Suit HD. The scope of the problem of primary tumor control. Cancer 1988;61: Perez CA, Breaux S, Bedwinek JM, Madoc Jones H, Camel HM, Purdy JA, et al. Radiation therapy alone in the treatment of carcinoma of the uterine cervix. II. Analysis of complications. Cancer 1984;54: Denekamp J. Changes in the rate of repopulation during multifraction irradiation of mouse skin. Br J Radiol 1973;46: Fowler JF. Potential for increasing the differential response between tumors and normal tissues: Can proliferation rate be used? Int J Radiat Oncol Biol Phys 1986;12: Baumann M, Liertz C, Baisch H, Wiegel T, Lorenzen J, Arps H. Impact of overall treatment time of fractionated irradiation on local control of human FaDu squamous cell carcinoma in nude mice. Radiother Oncol 1994;32: Oka K, Nakano T, Hoshi T. Transient increases of growth fraction during fractionated radiation therapy for cervical carcinoma. Ki 67 and PC10 immunostaining. Cancer 1993;72: Keane TJ, Fyles A, O Sullivan B, Barton M, Maki E, Simm J. The effect of treatment duration on local control of squamous carcinoma of the tonsil and carcinoma of the cervix. Semin Radiother Oncol 1992;2: Fyles A, Keane TJ, Barton M, Simm J. The effect of treatment duration in the local control of cervix cancer. Radiother Oncol 1992;25: Suguwara T, Mizutani Y, Nokazawa M, Ohkawara K. The effect of treatment time on pelvic recurrence in patients with stage III uterine cervix. Cancer J Jpn Ther Radiol Oncol 1993;5: Girinsky T, Rey A, Roche B, Haie C, Gerbaulet A, Randrianarivello H, et al. Overall treatment time in advanced cervical carcinomas: A critical parameter in treatment outcome. Int J Radiat Oncol Biol Phys 1993;27: Kapp KS, Stuecklschweiger GF, Kapp DS, Poschauko J, Pickel H, Hackl A. Carcinoma of the cervix: Analysis of complications after primary external beam radiation and Ir 192 HDR brachytherapy. Radiother Oncol 1997;42: How to cite this article: Bhagat P, Roy S, Lahiri D, Maji T, Ray DK, Biswas J, et al. Expedience of conventional radiotherapy in locally advanced cervix cancer: A retrospective analysis. Onc Gas Hep Rep 2015;4: Source of Support: Nil, Conflict of Interest: None declared. Oncology, Gastroenterology and Hepatology Reports Jul-Dec 2015 Vol 4 Issue 2 90
Concurrent chemoradiation in treatment of carcinoma cervix
N. J. Obstet. Gynaecol Vol. 2, No. 1, p. 4-8 May -June 2007 REVIEW Concurrent chemoradiation in treatment of carcinoma cervix Meeta Singh, Rajshree Jha, Josie Baral, Suniti Rawal Dept of Obs/Gyn, TU Teaching
More informationLong Term Outcome after Concurrent Chemo radiation with Cisplatin in Carcinoma Cervix
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 71.58 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i10.03 Long Term Outcome after Concurrent Chemo
More informationHigh-Dose-Rate Orthogonal Intracavitary Brachytherapy with 9 Gy/Fraction in Locally Advanced Cervical Cancer: Is it Feasible??
DOI 10.1007/s13224-015-0812-8 ORIGINAL ARTICLE High-Dose-Rate Orthogonal Intracavitary Brachytherapy with 9 Gy/Fraction in Locally Advanced Cervical Cancer: Is it Feasible?? Saptarshi Ghosh 1 Pamidimukalabramhananda
More informationNordic Society for Gynecological Oncology Advisory Board of Radiotherapy
Nordic Society for Gynecological Oncology Advisory Board of Radiotherapy Guidelines for postoperative irradiation of cervical cancer Contents: 1. Treatment planning for EBRT. 2 2. Target definition for
More informationINTRODUCTION. J. Radiat. Res., 53, (2012)
J. Radiat. Res., 53, 281 287 (2012) The Effects of Two HDR Brachytherapy Schedules in Locally Advanced Cervical Cancer Treated with Concurrent Chemoradiation: A Study from Chiang Mai, Thailand Ekkasit
More informationMETHODS. Study population. Treatment schedule
British Journal of Cancer (2007) 97, 1058 1062 All rights reserved 0007 0920/07 $30.00 www.bjcancer.com Treatment of squamous cell carcinoma of the uterine cervix with radiation therapy alone: long-term
More informationConcurrent chemoradiotherapy with low-dose daily cisplatin for high risk uterine cervical cancer: a long-term follow-up study
Original Article J Gynecol Oncol Vol. 24, No. 2:108-113 http://dx.doi.org/10.3802/jgo.2013.24.2.108 pissn 2005-0380 eissn 2005-0399 Concurrent chemoradiotherapy with low-dose daily cisplatin for high risk
More informationComparative Efficacy of Cisplatin vs. Gemcitabine as Concurrent Chemotherapy for Untreated Locally Advanced Cervical Cancer: A Randomized Trail
Comparative Efficacy of Cisplatin vs. Gemcitabine as Concurrent Chemotherapy for Untreated Locally Advanced Cervical Cancer: A Randomized Trail Dr. Nishee Srivastava MD, Dr. Kamal Sahani MD, Dr. Manoj
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX Site Group: Gynecology Cervix Author: Dr. Stephane Laframboise 1. INTRODUCTION 3 2. PREVENTION 3 3. SCREENING AND
More informationA profile of cervical cancer cases in a government medical college hospital
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 14, Issue 10 Ver.III (Oct. 2015), PP 37-42 www.iosrjournals.org A profile of cervical cancer cases in
More informationOriginal Date: June 2013 Page 1 of 7 Radiation Oncology Last Review Date: September Implementation Date: December 2014 Clinical Operations
National Imaging Associates, Inc. Clinical guideline CERVICAL CANCER Original Date: June 2013 Page 1 of 7 Radiation Oncology Last Review Date: September 2014 Guideline Number: NIA_CG_223 Last Revised Date:
More informationICRT รศ.พญ.เยาวล กษณ ชาญศ ลป
ICRT รศ.พญ.เยาวล กษณ ชาญศ ลป Brachytherapy การร กษาด วยร งส ระยะใกล Insertion การสอดใส แร Implantation การฝ งแร Surface application การวางแร physical benefit of brachytherapy - very high dose of radiation
More informationEarly clinical outcomes of 3D-conformal radiotherapy using. accelerated hyperfractionation without intracavitary brachytherapy
K. Matsuura, et al 1 Early clinical outcomes of 3D-conformal radiotherapy using accelerated hyperfractionation without intracavitary brachytherapy for cervical cancer K. Matsuura, M.D., Ph.D., a,b H. Tanimoto,
More informationChapter 5 Stage III and IVa disease
Page 55 Chapter 5 Stage III and IVa disease Overview Concurrent chemoradiotherapy (CCRT) is recommended for stage III and IVa disease. Recommended regimen for the chemotherapy portion generally include
More informationConcomitant chemo-radiation in locally advanced carcinoma of the cervix
J Obstet Gynecol India Vol. 57, No. 2: March/April 2007 Pg 145-150 ORIGINAL ARTICLE The Journal of Obstetrics and Gynecology of India Concomitant chemo-radiation in locally advanced carcinoma of the cervix
More informationINTRODUCTION PATIENT. J. Radiat. Res., 52, (2011)
J. Radiat. Res., 52, 54 58 (2011) Regular Paper Intracavitary Combined with CT-guided Interstitial Brachytherapy for Locally Advanced Uterine Cervical Cancer: Introduction of the Technique and a Case Presentation
More informationGYNECOLOGIC CANCER and RADIATION THERAPY. Jon Anders M.D. Radiation Oncology
GYNECOLOGIC CANCER and RADIATION THERAPY Jon Anders M.D. Radiation Oncology Brachytherapy Comes from the Greek brakhus meaning short Brachytherapy is treatment at short distance Intracavitary vs interstitial
More informationUPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER
UPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER Susan Davidson, MD Professor Department of Obstetrics and Gynecology Division of Gynecologic Oncology University of Colorado- Denver Anatomy Review
More informationWeekly Versus Triweekly Cisplatin-Based Chemotherapy Concurrent With Radiotherapy in the Treatment of Cervical Cancer
REVIEW ARTICLE Weekly Versus Triweekly Cisplatin-Based Chemotherapy Concurrent With Radiotherapy in the Treatment of Cervical Cancer A Meta-Analysis Xingxing Chen, MD,* Haizhou Zou, MD,Þ Huifang Li, MD,*
More informationPost operative Radiotherapy in Carcinoma Endometrium - KMIO Experience (A Retrospective Study)
Post operative Radiotherapy in Carcinoma Endometrium - KMIO Experience (A Retrospective Study) Sridhar.P, M.D. 1, Sruthi.K, M.D. 2, Naveen.T, M.D. 3, Siddanna.R.P, M.D. 4 Department of Radiation Oncology,
More informationDefinitions. Brachytherapy in treatment of cancer. Implantation Techniques and Methods of Dose Specifications. Importance of Brachytherapy in GYN
Implantation Techniques and Methods of Dose Specifications Brachytherapy Course Lecture V Krishna Reddy, MD, PhD Assistant Professor, Radiation Oncology Brachytherapy in treatment of cancer GYN Cervical
More informationCervical Cancer 3/25/2019. Abnormal vaginal bleeding
Cervical Cancer Abnormal vaginal bleeding Postcoital, intermenstrual or postmenopausal Vaginal discharge Pelvic pain or pressure Asymptomatic In most patients who are not sexually active due to symptoms
More informationOriginal Article ABSTRACT INTRODUCTION
Original Article Free full text available from www.cancerjournal.net Significance of ovoid separation with various applications of high-dose-rate-intracavitary radiotherapy in carcinoma of uterine cervix:
More informationJ Clin Oncol 22: by American Society of Clinical Oncology INTRODUCTION
VOLUME 22 NUMBER 5 MARCH 1 2004 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Pelvic Irradiation With Concurrent Chemotherapy Versus Pelvic and Para-Aortic Irradiation for High-Risk Cervical
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright, 1999, by the Massachusetts Medical Society VOLUME 340 A PRIL 15, 1999 NUMBER 15 PELVIC RADIATION WITH CONCURRENT CHEMOTHERAPY COMPARED WITH PELVIC AND PARA-AORTIC
More informationThe Effect of Treatment Time in Locally Advanced Cervical Cancer in the Era of Concurrent Chemoradiotherapy
The Effect of Treatment Time in Locally Advanced Cervical Cancer in the Era of Concurrent Chemoradiotherapy Suisui Song, MD 1 ; Sonali Rudra, MD 1 ; Michael D. Hasselle, MD 2 ; Paige L. Dorn, MD 1 ; Loren
More informationGynecologic Cancer InterGroup Cervix Cancer Research Network. Management of Cervical Cancer in Resource Limited Settings.
Management of Cervical Cancer in Resource Limited Settings Linus Chuang MD Conflict of Interests None Cervical cancer is the fourth most common malignancy in women worldwide 530,000 new cases per year
More informationIsolated Para-Aortic Lymph Nodes Recurrence in Carcinoma Cervix
J Nepal Health Res Counc 2009 Oct;7(15):103-7 Original Article Isolated Para-Aortic Lymph Nodes Recurrence in Carcinoma Cervix Ghimire S 1, Hamid S, 2 Rashid A 2 1 Bhaktapur Cancer Hospital, Bhaktapur,
More informationJMSCR Vol 06 Issue 12 Page December 2018
www.jmscr.igmpublication.org Impact Factor (SJIF): 6.379 Index Copernicus Value: 79.54 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v6i12.129 Research Paper Establishing
More informationhttps://patient.varian.com/sit es/default/files/videos/origin al/imrt.mp4 brachy- from Greek brakhys "short" Historically LDR has been used. Cs-137 at 0.4-0.8 Gy/h With optimally placed device, dose
More informationPostoperative Radiotherapy for Patients with Invasive Cervical Cancer Following Treatment with Simple Hysterectomy
Jpn J Clin Oncol 2003;33(9)477 481 Postoperative Radiotherapy for Patients with Invasive Cervical Cancer Following Treatment with Simple Hysterectomy Shang-Wen Chen 1,2, Ji-An Liang 1,2, Shih-Neng Yang
More informationLocally advanced disease & challenges in management
Gynecologic Cancer InterGroup Cervix Cancer Research Network Cervix Cancer Education Symposium, February 2018 Locally advanced disease & challenges in management Carien Creutzberg Radiation Oncology, Leiden
More informationEvaluation of Survival and Treatment Toxicity With High-Dose-Rate Brachytherapy With Cobalt 60 In Carcinoma of Cervix
Iran J Cancer Preven. 2015 August; 8(4):e3573. Published online 2015 August 24. DOI: 10.17795/ijcp-3573 Research Article Evaluation of Survival and Treatment Toxicity With High-Dose-Rate Brachytherapy
More informationIs Prophylactic Irradiation to Para-aortic Lymph Nodes in Locally Advanced Cervical Cancer Necessary?
pissn 1598-2998, eissn 2005-9256 Cancer Res Treat. 2014;46(4):374-382 Original Article http://dx.doi.org/10.4143/crt.2013.084 Open Access Is Prophylactic Irradiation to Para-aortic Lymph Nodes in Locally
More informationOutcomes and prognostic factors of cervical cancer after concurrent chemoradiationjog_
bs_bs_banner doi:10.1111/j.1447-0756.2012.01871.x J. Obstet. Gynaecol. Res. Vol. 38, No. 11: 1315 1320, November 2012 Outcomes and prognostic factors of cervical cancer after concurrent chemoradiationjog_1871
More informationOriginal Article INTRODUCTION. Abstract
Original Article Print ISSN: 2321-6379 Online ISSN: 2321-595X DOI: 10.17354/ijss/2018/251 A Prospective Analysis of Toxicities and Quality of Life after Treatment in Advanced Carcinoma Cervix Patients
More informationKEY WORDS: Carcinoma cervix, high-dose-rate brachytherapy, radiotherapy
Technical Report Free full text available from www.cancerjournal.net Vandana S Jain, Mukund B Sarje, Kailash K Singh, R Umberkar, Rajeev Shrivastava, Shailendra M Jain Department of Radiotherapy and Clinical
More informationEditorial Process: Submission:09/12/2017 Acceptance:06/19/2018
DOI:10.22034/APJCP.2018.19.10.2745 Concurrent Chemo-Radiobrachytherapy in Cervical Cancer RESEARCH ARTICLE Editorial Process: Submission:09/12/2017 Acceptance:06/19/2018 Concurrent Chemo- Radiobrachytherapy
More informationORIGINAL PAPER. Departments of Radiology, Nagoya University Graduate School of Medicine, Nagoya Japan 2
Nagoya J. Med. Sci. 76. 11 ~ 16, 2014 ORIGINAL PAPER RETROSPECTIVE CASE SERIES OF 15 PATIENTS TREATED WITH CHEMORADIATION USING 5-FU AND NEDAPLATIN FOR GYNECOLOGICAL MALIGNANCY: WITH REGARD TO HEMOTOXICITY
More informationINTRODUCTION. Taek Keun Nam, Sung Ja Ahn
J Korean Med Sci 2004; 19: 87-94 ISSN 1011-8934 Copyright The Korean Academy of Medical Sciences A Prospective Randomized Study on Two Dose Fractionation Regimens of High-Dose-Rate Brachytherapy for Carcinoma
More informationPelvic palliative radiotherapy for gynecological cancers present state of knowledge and pending research questions to answer
Pelvic palliative radiotherapy for gynecological cancers present state of knowledge and pending research questions to answer Esten S. Nakken MD PhD Division of Cancer Medicine Oslo University Hospital
More informationRESEARCH ARTICLE. Kuanoon Boupaijit, Prapaporn Suprasert* Abstract. Introduction. Materials and Methods
RESEARCH ARTICLE Survival Outcomes of Advanced and Recurrent Cervical Cancer Patients Treated with Chemotherapy: Experience of Northern Tertiary Care Hospital in Thailand Kuanoon Boupaijit, Prapaporn Suprasert*
More informationConcurrent chemoradiation in locally advanced carcinoma cervix patients
Original Article Free full text available from www.cancerjournal.net Concurrent chemoradiation in locally advanced carcinoma cervix patients ABSTRACT Purpose: To investigate the feasibility of concurrent
More informationComparison of rectal and bladder ICRU point doses to the GEC ESTRO volumetric doses in Cervix cancer
Comparison of rectal and bladder ICRU point doses to the GEC ESTRO volumetric doses in Cervix cancer Poster No.: RO-0049 Congress: RANZCR FRO 202 Type: Authors: Scientific Exhibit G. Govindarajulu, A.
More informationHypofractionated RT in Cervix Cancer. Anuja Jhingran, MD
Hypofractionated RT in Cervix Cancer Anuja Jhingran, MD Hypofractionated RT in Cervix Cancer: Clinicaltrials.gov 919 cervix trials 134 hypofractionated RT trials Prostate, breast, NSCLC, GBM 0 cervix trials
More informationAdjuvant Therapies in Endometrial Cancer. Emma Hudson
Adjuvant Therapies in Endometrial Cancer Emma Hudson Endometrial Cancer Most common gynaecological cancer Incidence increasing in Western world 1-2% cancer deaths 75% patients postmenopausal 97% epithelial
More informationEui-Sok Sol 1, Tae Sung Lee 1, Suk Bong Koh 1, Hun Kyu Oh 2, Gi Won Ye 3, Youn Seok Choi 1 INTRODUCTION
J Gynecol Oncol Vol. 20, No. 1:28-34, March 2009 DOI:10.3802/jgo.2009.20.1.28 Original Article Comparison of concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil versus cisplatin plus paclitaxel
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org High Dose Rate Brachytherapy in Cervix Cancer Luis Souhami, MD Professor Department of Radiation Oncology
More informationInterstitial Brachytherapy. Low dose rate brachytherapy. Brachytherapy alone cures some cervical cancer. Learning Objectives
Interstitial Learning Objectives To discuss practical aspects of selection and insertion techniques for interstitial brachytherapy and their relation to clinical trials Akila Viswanathan, MD MPH Johns
More informationSigmoid Colon is an Unexpected Organ at Risk in Brachytherapy for Cervix Cancer
Journal of the Egyptian Nat. Cancer Inst., Vol. 18, No. 2, June: 156-160, 2006 Sigmoid Colon is an Unexpected Organ at Risk in Brachytherapy for Cervix Cancer HODA AL-BOOZ, FRCR FFRRCSI M.D.*; ION BOIANGIU,
More informationVagina. 1. Introduction. 1.1 General Information and Aetiology
Vagina 1. Introduction 1.1 General Information and Aetiology The vagina is part of internal female reproductive system. It is an elastic, muscular tube that connects the outside of the body to the cervix.
More informationchemoradiation. Each of these trials had slightly different interventions,
Research ONCOLOGY Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial Frederick B. Stehman, MD; Shamshad Ali, MS, MStat;
More informationCervical cancer presentation
Carcinoma of the cervix: Carcinoma of the cervix is the second commonest cancer among women worldwide, with only breast cancer occurring more commonly. Worldwide, cervical cancer accounts for about 500,000
More informationPatterns of Care in Patients with Cervical Cancer:
Patterns of Care in Patients with Cervical Cancer: Power and Pitfalls of Claims-Based Analysis Grace Smith, MD, PhD, MPH Resident, PGY-5 Department of Radiation Oncology, MD Anderson Cancer Center Acknowledgments
More informationD. LONG, H. FRIEDRICH-NEL, L. GOEDHALS AND G. JOUBERT
HIGH DOSE-RATE BRACHYTHERAPY IN THE RADICAL TREATMENT OF CERVICAL CANCER. AN ANALYSIS OF DOSE EFFECTIVENESS AND INCIDENCE OF LATE RADIATION COMPLICATIONS D. LONG, H. FRIEDRICH-NEL, L. GOEDHALS AND G. JOUBERT
More informationMRI in Cervix and Endometrial Cancer
28th Congress of the Hungarian Society of Radiologists RCR Session Budapest June 2016 MRI in Cervix and Endometrial Cancer DrSarah Swift St James s University Hospital Leeds, UK Objectives Cervix and endometrial
More informationORIGINAL ARTICLE. Summary. Introduction
Journal of BUON 17: 740-745, 2012 2012 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Cisplatin monotherapy with concurrent radiotherapy versus combination of cisplatin and 5-fluorouracil
More informationCalculation of organs radiation dose in cervical carcinoma external irradiation beam using day s methods
Global Advanced Research Journal of Medicine and Medical Science (ISSN: 2315-5159) Vol. 3(5) pp. 090-094, May 2014 Available online http://garj.org/garjmms/index.htm Copyright 2014 Global Advanced Research
More informationVaginal intraepithelial neoplasia
Vaginal intraepithelial neoplasia The terminology and pathology of VAIN are analogous to those of CIN (VAIN I-III). The main difference is that vaginal epithelium does not normally have crypts, so the
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Carcinoma of the Uterine Cervix
THIS DOCUMENT North of Scotland Cancer Network Carcinoma of the Uterine Cervix UNCONTROLLED WHEN PRINTED DOCUMENT CONTROL Prepared by A Kennedy/AG Macdonald/Others Approved by NOT APPROVED Issue date April
More informationCase Scenario 1. History
History Case Scenario 1 A 53 year old white female presented to her primary care physician with post-menopausal vaginal bleeding. The patient is not a smoker and does not use alcohol. She has no family
More informationPragyat Thakur 1,2, Rajeev Seam 1, Manoj Gupta 1, Manish Gupta 1. Introduction
Original Article on Newer Agents to Enhance Radiotherapeutic Outcomes Page 1 of 8 Prospective randomized study comparing concomitant chemoradiotherapy using weekly cisplatin & paclitaxel versus weekly
More informationCOX-2 inhibitor and irradiation. Saitama Cancer Center Kunihiko Kobayashi MD, PhD
COX-2 inhibitor and irradiation Saitama Cancer Center Kunihiko Kobayashi MD, PhD Synthesis of prostaglandins from arachidonic acid by cyclooxygenase (COX) enzymes JNCI 95:1440, 2003 Difference between
More informationDose-Volume Histogram Analysis in Point A-based Dose Prescription of High-dose-rate Brachytherapy for Cervical Carcinoma
Showa Univ J Med Sci 30 2, 227 235, June 2018 Original Dose-Volume Histogram Analysis in Point A-based Dose Prescription of High-dose-rate Brachytherapy for Cervical Carcinoma Rei KOBAYASHI 1, Yoshikazu
More informationProspective comparative study of dose dense neo-adjuvant chemotherapy followed by chemo-radiation and definitive chemoradiation
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Karpurmath SV et al. Int J Reprod Contracept Obstet Gynecol. 2016 Sept;5(9):2909-2914 www.ijrcog.org pissn 2320-1770 eissn
More informationCARCINOMA CERVIX. Dr. PREETHI REDDY. B. M S OBG II yr POST GRADUATE.
CARCINOMA CERVIX Dr. PREETHI REDDY. B M S OBG II yr POST GRADUATE. Introduction Cervical cancer is the second most common female malignancy worldwide. It is responsible for 4,66,000 deaths annually worldwide
More informationA Study on Dosimetry of Gynaecological Cancer and Quality Assurance of HDR Brachytherapy in BPKMCH, Nepal
A Study on Dosimetry of Gynaecological Cancer and Quality Assurance of HDR Brachytherapy in BPKMCH, Nepal SB Chand, PP Chaursia, MP Adhikary, AK Jha, and S Shrestha Dept. of Radiation Oncology, BPKM Cancer
More informationRadiation Oncology MOC Study Guide
Radiation Oncology MOC Study Guide The following study guide is intended to give a general overview of the type of material that will be covered on the Radiation Oncology Maintenance of Certification (MOC)
More informationPORTEC-4. Patient seqnr. Age at inclusion (years) Hospital:
May 2016 Randomisation Checklist Form 1, page 1 of 2 Patient seqnr. Age at inclusion (years) Hospital: Eligible patients should be registered and randomised via the Internet at : https://prod.tenalea.net/fs4/dm/delogin.aspx?refererpath=dehome.aspx
More informationAn Unusual Case of Cervical Cancer with Inguinal Lymph Node Metastasis: A Case Report and Review of the Literature
Archives of Clinical and Medical Case Reports doi: 10.26502/acmcr.9655003 Volume 1, Issue 1 Case Report An Unusual Case of Cervical Cancer with Inguinal Lymph Node Metastasis: A Case Report and Review
More informationConcurrent Weekly Taxol Versus Weekly Cisplatin with Radiotherapy in the Treatment of Locally Advanced Cervical Cancer
Med. J. Cairo Univ., Vol. 82, No. 2, March: 351-357, 2014 www.medicaljournalofcairouniversity.net Concurrent Weekly Taxol Versus Weekly Cisplatin with Radiotherapy in the Treatment of Locally Advanced
More informationRadiotherapy & Cervical Cancer Dr Mary McCormack Consultant Clinical Oncologist University College Hospital, London,UK
Lead Group Log Radiotherapy & Cervical Cancer Dr Mary McCormack Consultant Clinical Oncologist University College Hospital, London,UK Cervical Cancer treatment Treatment planning should be made on a multidisciplinary
More informationImpact of Radiotherapy with and without Concurrent Cisplatin on Lymphocyte Subpopulations in Cervical Cancer Patients
Impact of Radiotherapy with and without Concurrent Cisplatin on Lymphocyte Subpopulations in Cervical Cancer Patients BARBARA BACHTIARY 1, IRENE HERBACEK 2, THOMAS ZIDECK 2, THOMAS-HENDRIK KNOCKE 1, JOHANNES
More informationfor the Degree of Master of Medicine in Radiation oncology WONDEMAGEGNHU TIGENEH MB. Ch. B, FCR (Onc) SA. Division of Radiation Oncology
A Prospective Randomized Study Comparing Three-Fraction Regimens of HDR Brachytherapy with concomitant chemo-radiotherapy for Cancer of the Cervix Stage IIB and IIIB A thesis submitted to the faculty of
More informationConcurrent chemoradiation versus radiotherapy alone in cervical carcinoma: A randomized phase III trial
bs_bs_banner Asia Pacific Journal of Clinical Oncology 2013; 9: 349 356 doi: 10.1111/ajco.12078 ORIGINAL ARTICLE Concurrent chemoradiation versus radiotherapy alone in cervical carcinoma: A randomized
More informationIntra-operative frozen section analysis of common iliac lymph nodes in patients with stage IB1 and IIA1 cervical cancer
Arch Gynecol Obstet (2012) 285:811 816 DOI 10.1007/s00404-011-2038-z GYNECOLOGIC ONCOLOGY Intra-operative frozen section analysis of common iliac lymph nodes in patients with stage IB1 and IIA1 cervical
More informationPrognostic factors and treatment outcome after radiotherapy in cervical cancer patients with isolated para-aortic lymph node metastases
Original Article J Gynecol Oncol Vol. 24, No. 3:229-235 pissn 2005-0380 eissn 2005-0399 Prognostic factors and treatment outcome after radiotherapy in cervical cancer patients with isolated para-aortic
More informationARROCase: Locally Advanced Endometrial Cancer
ARROCase: Locally Advanced Endometrial Cancer Charles Vu, MD (PGY-3) Faculty Advisor: Peter Y. Chen, MD, FACR Beaumont Health (Royal Oak, MI) November 2016 Case 62yo female with a 3yr history of vaginal
More informationAOGS MAIN RESEARCH ARTICLE
A C TA Obstetricia et Gynecologica AOGS MAIN RESEARCH ARTICLE Differential clinical characteristics, treatment response and prognosis of locally advanced adenocarcinoma/ adenosquamous carcinoma and squamous
More informationImage based Brachytherapy- HDR applications in Gynecological Tumors
Image based Brachytherapy- HDR applications in Gynecological Tumors Yakov Pipman, D. Sc. North Shore LIJ Health System Sites amenable to treatment with HDR Brachytherapy GYN Breast Prostate Head and Neck
More informationStaging. Carcinoma confined to the corpus. Carcinoma confined to the endometrium. Less than ½ myometrial invasion. Greater than ½ myometrial invasion
5 th of June 2009 Background Most common gynaecological carcinoma in developed countries Most cases are post-menopausal Increasing incidence in certain age groups Increasing death rates in the USA 5-year
More informationCombined Modality Treatment of Anal Carcinoma
Combined Modality Treatment of Anal Carcinoma F. ROELOFSEN, a H. BARTELINK b a Bethesda Krankenhaus, Essen, Germany; b The Netherlands Cancer Institute/Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, The
More informationTREATMENT TIME & TOBACCO: TWIN TERRORS Of H&N Therapy
TREATMENT TIME & TOBACCO: TWIN TERRORS Of H&N Therapy Anurag K. Singh, MD Professor of Medicine University at Buffalo School of Medicine Professor of Oncology Director of Radiation Research Roswell Park
More informationJOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 6, NUMBER 2, SPRING 2005
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 6, NUMBER 2, SPRING 2005 Advantages of inflatable multichannel endorectal applicator in the neo-adjuvant treatment of patients with locally advanced
More informationProposed All Wales Vulval Cancer Guidelines. Dr Amanda Tristram
Proposed All Wales Vulval Cancer Guidelines Dr Amanda Tristram Previous FIGO staging FIGO Stage Features TNM Ia Lesion confined to vulva with
More informationCountry Presentations of FNCA FY2007 Workshop on Radiation Oncology
Country Presentations of FNCA FY2007 Workshop on Radiation Oncology Annex 3 Country presentations on CERVIX-III -China: Total Patients: 18, 8 alive: 1 with metastasis lung, another one metastasis to liver;
More informationEnterprise Interest None
Enterprise Interest None Cervical Cancer -Management of late stages ESP meeting Bilbao Spain 2018 Dr Mary McCormack PhD FRCR Consultant Clinical Oncologist University College Hospital London On behalf
More informationRole of Twice Weekly HDR- Brachytherapy in Management of Carcinoma Of Uterine Cervix-Experience of Rural Centre in India
Global Journal of Medical research Interdsciplinary Volume 13 Issue 4 Version 1.0 Year 2013 Type: Double Blind Peer Reviewed International Research Journal Publisher: Global Journals Inc. (USA) Online
More informationDepartment of Radiotherapy, Pt. BDS PGIMS, Rohtak, Haryana, India
Bharti et al., IJPSR, 2010; Vol. 1 (11): 169-173 ISSN: 0975-8232 IJPSR (2010), Vol. 1, Issue 11 (Research Article) Received on 29 September, 2010; received in revised form 21 October, 2010; accepted 26
More informationAdjuvant Chemotherapy in High Risk Patients after Wertheim Hysterectomy 10-year Survivals
6 Adjuvant Chemotherapy in High Risk Patients after Wertheim Hysterectomy 0-year Survivals V Sivanesaratnam,*FAMM, FRCOG, FACS Abstract Although the primary operative mortality following radical hysterectomy
More informationThree fraction high dose rate brachytherapy schedule for treatment of locally advanced uterine cervix cancer center:
Huerta et al, Cancerología 3 (008): 105-110 Three fraction high dose rate brachytherapy schedule for treatment of locally advanced uterine cervix cancer center: Clinical results, emphasis in dosimetric
More informationStudy Title The SACS trial - Phase II Study of Adjuvant Therapy in CarcinoSarcoma of the Uterus
Study Title The SACS trial - Phase II Study of Adjuvant Therapy in CarcinoSarcoma of the Uterus Investigators Dr Bronwyn King, Peter MacCallum Cancer Centre Dr Linda Mileshkin, Peter MacCallum Cancer Centre
More informationThe New England Journal of Medicine
CISPLATIN, RADIATION, AND ADJUVANT HYSTERECTOMY COMPARED WITH RADIATION AND ADJUVANT HYSTERECTOMY FOR BULKY STAGE IB CERVICAL CARCINOMA HENRY M. KEYS, M.D., BRIAN N. BUNDY, PH.D., FREDERICK B. STEHMAN,
More informationRadiation therapy with chemotherapy for patients with cervical cancer and supraclavicular lymph node involvement
Original Article J Gynecol Oncol Vol. 23, No. 3:159-167 pissn 2005-0380 eissn 2005-0399 Radiation therapy with chemotherapy for patients with cervical cancer and supraclavicular lymph node involvement
More informationOral cavity cancer Post-operative treatment
Oral cavity cancer Post-operative treatment Dr. Christos CHRISTOPOULOS Radiation Oncologist Centre Hospitalier Universitaire (C.H.U.) de Limoges, France Important issues RT -techniques Patient selection
More information3D ANATOMY-BASED PLANNING OPTIMIZATION FOR HDR BRACHYTHERAPY OF CERVIX CANCER
SAUDI JOURNAL OF OBSTETRICS AND GYNECOLOGY VOLUME 11 NO. 2 1430 H - 2009 G 3D ANATOMY-BASED PLANNING OPTIMIZATION FOR HDR BRACHYTHERAPY OF CERVIX CANCER DR YASIR BAHADUR 1, DR CAMELIA CONSTANTINESCU 2,
More information3/8/2014. Case Presentation. Primary Treatment of Anal Cancer. Anatomy. Overview. March 6, 2014
Case Presentation Primary Treatment of Anal Cancer 65 year old female presents with perianal pain, lower GI bleeding, and anemia with Hb of 7. On exam 6 cm mass protruding through the anus with bulky R
More informationComparison of concurrent chemoradiation therapy with weekly cisplatin versus monthly fluorouracil plus cisplatin in FIGO stage IIB-IVA cervical cancer
Original Article J Gynecol Oncol Vol. 23, No. 4:235-241 pissn 2005-0380 eissn 2005-0399 Comparison of concurrent chemoradiation therapy with weekly cisplatin versus monthly fluorouracil plus cisplatin
More informationChallenging Cases in Cervical Cancer: Parametrial Boosting. Beth Erickson, MD, FACR, FASTRO Medical College Wisconsin
Challenging Cases in Cervical Cancer: Parametrial Boosting Beth Erickson, MD, FACR, FASTRO Medical College Wisconsin Disclosure Chart Rounds participant No COI Learning Objectives Discuss the challenges
More informationHYPERTHERMIA in CERVIX and VAGINA CANCER. J. van der Zee
HYPERTHERMIA in CERVIX and VAGINA CANCER J. van der Zee ESTRO 2006 Deep hyperthermia in Rotterdam HYPERTHERMIA in CERVIX and VAGINA CANCER ESTRO 2006 Hyperthermia and radiotherapy in primary advanced cervix
More information